RheinCell Therapeutics GmbH focuses on the GMP-compliant generation of human induced pluripotent stem cells (iPSC) from HLA-homozygous allogeneic umbilical cord blood (CB).
The field of cell therapy is one of the most promising developments in modern medicine. But autologous approaches – based on cells made patient-by-patient – are extremely expensive and time consuming and thus, unsuited for routine applications. Instead, regenerative cell therapy requires allogenic off-the-shelf therapeutics.
Our main focus is on setting up an iPS cell library consisting of various HLA-homozygous iPS master cell banks. The key idea behind is that only a limited number of iPSC lines are needed to set up an allogenic resource which prevents immune rejections in a large number of recipient patients. Thus, this master cell library serves as “off the shelf”- platform for various types of cell therapeutics and has the potential to become the starting material of any future iPSC-based cell therapy in the Western world – and beyond.